Term ends Mar 10, 2031 · High confidence
20-year base term ends Mar 10, 2031
Mar 10, 2011
Mar 10, 2031
Jan 7, 2020
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 2 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Mar 10, 2011, when application PCT/GB2011/050472, the earliest non-provisional in its chain, was filed (this one was filed Aug 20, 2018) | Mar 10, 2031 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,085,970, US 8,686,019, US 9,084,765, US 9,119,836, US 9,545,426, US 9,889,118) | resolves to Mar 10, 2031, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Mar 10, 2031 | High confidence |
This family
| US 9,084,765 | In force Feb 2034 | Feb 2034 |
| US 8,686,019 | In force Mar 2031 | Mar 2031 |
| US 9,119,836 | In force Mar 2031 | Mar 2031 |
| US 9,545,426 | In force Mar 2031 | Mar 2031 |
| US 9,889,118 | In force Mar 2031 | Mar 2031 |
| US 10,085,970 | In force Mar 2031 | Mar 2031 |
| US 10,525,033 | this patent Mar 2031 | Mar 2031 |
| Application 16/697,986 | Abandoned not computed | not computed |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Aug 21, 2018 Reel 46640, frame 639 | Gilbert, Julian Clive; Gristwood, Robert William; Cooper, Nicola; Fox, Gabriel | Acacia Pharma Limited | Assignment of Assignor's Interest |
| Apr 28, 2023 Reel 63476, frame 631 | Acacia Pharma Limited | JPMorgan Chase Bank, N.A., as Administrative Agent | Security Interest |
| Apr 1, 2025 Reel 70698, frame 351 | JPMorgan Chase Bank, N.A., as Administrative Agent | Acacia Pharma Limited | Release of Security Interest |
| Mar 4, 2026 Reel 73967, frame 303 | Acacia Pharma Limited; Acacia Pharma, Inc.; Eagle Pharmaceuticals, Inc. | Lxo Ireland Designated Activity Company; Lxo US, Inc. | Assignment of Assignor's Interest |
| Mar 4, 2026 reel/frame not recorded | Acacia Pharma Limited; Acacia Pharma, Inc.; Eagle Pharmaceuticals, Inc. | Lxo Ireland Designated Activity Company | Assignment of Assignor's Interest |
| Mar 4, 2026 reel/frame not recorded | Acacia Pharma Limited; Acacia Pharma, Inc.; Eagle Pharmaceuticals, Inc. | Lxo US, Inc. | Assignment of Assignor's Interest |
| Apr 27, 2026 Reel 74483, frame 163 | Lxo Ireland Designated Activity Company | Kroll Trustee Services Limited, as Security Agent | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 10,085,970, US 8,686,019, US 9,084,765, US 9,119,836, US 9,545,426, US 9,889,118, ends no earlier than this term, so it caps nothing.